 |
|
|
| |
Dolutegravir plus lamivudine maintains HIV-1 suppression
through week 48 in a pilot randomized trial (ASPIRE)
|
| |
| |
Reported by Jules Levin
EACS - 16th European AIDS Conference, October 25-27, 2017. Milan
1Babafemi O. Taiwo, 2Vincent Marconi, 1Baiba Berzins, 3Carlee Moser, 4Amesika N. Nyaku, 5Carl J. Fichtenbaum, 6Timothy Wilkin, 7Constance A. Benson, 8Susan L. Koletar, 2Jonathan Colasanti, 9Jonathan Li, 9Paul E. Sax, and the ASPIRE Team 1Northwestern University, Infectious Diseases, Chicago, U.S., 2Emory University, Atlanta, U.S., 3Harvard School of Public Health, Boston, U.S., 4Rutgers, Newark, U.S., 5University of Cincinnati, Cincinnati, U.S., 6Cornell University, New York, U.S., 7University of California, San Diego, U.S., 8The Ohio State University, Columbus, U.S., 9Brigham and Women's Hospital, Boston, U.S.,
|
| |
|
|
|
|
|
